An Evidence-Based Drug Update & Guidance for Rheumatologists

“Reimbursement for this test is still in evolution,” said Dr. Curtis, “but this [test] is something you could choose to order for a patient when picking an RA drug. At this point, the test is most well studied in biologic-naive patients.”

Summary

New therapies and laboratory tests have the potential to profoundly affect patient care. Dr. Curtis highlighted the pluses and minuses, providing evidence-based guidance for the rheumatology community.

Samantha C. Shapiro, MD, is an academic rheumatologist and an affiliate faculty member of the Dell Medical School at the University of Texas at Austin. She is also a member of the ACR Insurance Subcommittee.

References

1. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020 Jan 16;382(3):211–221.
2. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070–2080.
3. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020 Oct;8(10):963–974.
4. Roofeh D, Lin CJF, Goldin J, et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2021 Jul;73(7):1301–1310.
5. Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021 Jul 8;385(2):130–141.
6. Strand V, Cohen SB, Curtis JR, et al. Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: An analysis from the study to accelerate information of molecular signatures (AIMS) in rheumatoid arthritis. Expert Rev Mol Diagn. 2022 Jan;22(1):101–109.